

Interactions with HDV Treatment

Charts created July 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
Anaesthetics and muscle relaxants	
Bupivacaine	◆
Cisatracurium	◆
Desflurane	◆
Dexmedetomidine	◆
Ephedrine	◆
Etidocaine	◆
Halothane	◆
Isoflurane	◆
Ketamine	◆
Nitrous oxide	◆
Propofol	◆
Remifentanyl	◆
Rocuronium	◆
Sevoflurane	◆
Tetracaine	◆
Thiopental	◆
Tizanidine	◆
Analgesics	
Acetofenac	◆
Alfentanil	◆
Aspirin	◆
Buprenorphine	◆
Celecoxib	◆
Codeine	◆
Dexketoprofen	◆
Dextropropoxyphene	◆
Diamorphine	◆
Diclofenac	◆
Diflunisal	◆
Dihydrocodeine	◆
Etoricoxib	◆
Fentanyl (Prescribed)	◆
Flurbiprofen	◆
Hydrocodone	◆
Hydromorphone	◆
Ibuprofen	◆
Indometacin	◆
Ketoprofen	◆
Mefenamic acid	◆
Meloxicam	◆
Metamizole (Dipyrone)	◆
Methadone	◆
Morphine	◆
Naproxen	◆
Nefopam	◆
Oxycodone	◆
Paracetamol	◆
Pethidine (Meperidine)	◆
Piroxicam	◆
Tapentadol	◆
Tramadol	◆
Anthelmintics	
Albendazole	◆
Ivermectin	◆
Niclosamide	◆
Oxamniquine	◆
Praziquantel	◆
Pyrantel	◆
Antiarrhythmics	
Amiodarone	◆
Bepridil	◆
Digoxin	◆
Disopyramide	◆
Dofetilide	◆
Dronedarone	◆
Flecainide	◆
Lidocaine (Lignocaine)	◆
Mexiletine	◆
Propafenone	◆
Quinidine	◆
Vernakalant	◆

For personal use only. Not for distribution.

	Bulevirtide
Antibacterials	
Amikacin	◆
Amoxicillin	◆
Ampicillin	◆
Azithromycin	◆
Aztreonam	◆
Bedaquiline	◆
Benzyloxyphenacillin	◆
Capreomycin	◆
Cefaclor	◆
Cefadroxil	◆
Cefalexin	◆
Cefazolin	◆
Cefixime	◆
Cefotaxime	◆
Cefradine	◆
Ceftaroline	◆
Ceftazidime	◆
Ceftriaxone	◆
Cefuroxime	◆
Chloramphenicol	◆
Ciprofloxacin	◆
Clarithromycin	◆
Clavulanic acid	◆
Clindamycin	◆
Clofazimine	◆
Cloxacillin	◆
Cycloserine	◆
Dapsone	◆
Daptomycin	◆
Delamanid	◆
Ertapenem	◆
Erythromycin	◆
Ethambutol	◆
Flucloxacillin	◆
Fosfomycin	◆
Gentamicin	◆
Imipenem	◆
Isoniazid	◆
Levofloxacin	◆
Linezolid	◆
Lymecycline	◆
Meropenem	◆
Methanamine	◆
Metronidazole	◆
Moxifloxacin	◆
Nitrofurantoin	◆
Norfloxacin	◆
Ofloxacin	◆
Penicillin V	◆
Piperacillin	◆
Pivmecillinam	◆
Pretomanid	◆
Pyrazinamide	◆
Rifabutin	◆
Rifampicin	◆
Rifapentine	◆
Rifaximin	▲
Spectinomycin	◆
Streptomycin	◆
Sulfadiazine	◆
Tazobactam	◆
Telithromycin	◆
Temocillin	◆
Tetracyclines	◆
Ticarcillin	◆
Trimethoprim/Sulfamethoxazole	◆
Troleandomycin	◆

For personal use only. Not for distribution.

	Bulevirtide
Anticoagulant, Anti-Platelet & Fibrinolytic	
Abciximab	◆
Acenocoumarol	◆
Anagrelide	◆
Apixaban	◆
Caplacizumab	◆
Clopidogrel	◆
Dabigatran	◆
Dalteparin	◆
Danaparoid	◆
Dipyridamole	◆
Edoxaban	◆
Enoxaparin	◆
Fluindione	◆
Fondaparinux	◆
Heparin	◆
Natalizumab	◆
Phenprocoumon	◆
Prasugrel	◆
Rivaroxaban	◆
Streptokinase	◆
Ticagrelor	◆
Ticlopidine	◆
Tinzaparin	◆
Warfarin	◆
Anticonvulsants	
Carbamazepine	◆
Clonazepam	◆
Eslicarbazepine	◆
Ethosuximide	◆
Gabapentin	◆
Lacosamide	◆
Lamotrigine	◆
Levetiracetam	◆
Oxcarbazepine	◆
Perampanel	◆
Phenobarbital	◆
Phenytoin	◆
Pregabalin	◆
Primidone	◆
Retigabine	◆
Rufinamide	◆
Sultiame	◆
Tiagabine	◆
Topiramate	◆
Valproic acid (Divalproex)	◆
Vigabatrin	◆
Zonisamide	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HDV Treatment

Charts created July 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
Antidepressants	
Agomelatine	◆
Amitriptyline	◆
Bupropion	◆
Citalopram	◆
Clomipramine	◆
Desipramine	◆
Desvenlafaxine	◆
Dosulepin	◆
Doxepin	◆
Duloxetine	◆
Escitalopram	◆
Fluoxetine	◆
Fluvoxamine	◆
Imipramine	◆
Lithium	◆
Maprotiline	◆
Mianserin	◆
Milnacipran	◆
Mirtazapine	◆
Moclobemide	◆
Nefazodone	◆
Nortriptyline	◆
Paroxetine	◆
Phenelzine	●
Reboxetine	◆
Sertraline	◆
Tianeptine	◆
Trazodone	◆
Trimipramine	◆
Venlafaxine	◆
Vortioxetine	◆
Antidiabetics	
Acarbose	◆
Albiglutide	◆
Alogliptin	◆
Canagliflozin	◆
Dapagliflozin	◆
Dulaglutide	◆
Empagliflozin	◆
Exenatide	◆
Glibenclamide (Glyburide)	■
Gliclazide	◆
Glimepiride	◆
Glipizide	◆
Insulin	◆
Linagliptin	◆
Liraglutide	◆
Lixisenatide	◆
Metformin	◆
Nateglinide	◆
Pioglitazone	◆
Repaglinide	◆
Rosiglitazone	◆
Saxagliptin	◆
Semaglutide	◆
Sitagliptin	◆
Tirzepatide	◆
Tolbutamide	◆
Vildagliptin	◆

For personal use only. Not for distribution.

	Bulevirtide
Antifungals	
Amphotericin B	◆
Anidulafungin	◆
Caspofungin	◆
Clotrimazole (pessary)	◆
Clotrimazole (topical)	◆
Fluconazole	◆
Flucytosine	◆
Griseofulvin	◆
Isavuconazole	◆
Itraconazole	◆
Ketoconazole	●
Miconazole	◆
Nystatin	◆
Posaconazole	◆
Terbinafine	◆
Voriconazole	◆
Antihemorrhagics	
Avatrombopag	◆
Eltrombopag	◆
Tranexamic acid	◆
Antihistamines	
Astemizole	■
Bilastine	◆
Cetirizine	◆
Chlorphenamine	◆
Desloratadine	◆
Diphenhydramine	◆
Doxylamine	◆
Ebastine	■
Fexofenadine	■
Hydroxyzine	◆
Levocetirizine	◆
Loratadine	◆
Lomexigal	◆
Promethazine	◆
Terfenadine	■
Antimigraine Agents	
Almotriptan	◆
Dihydroergotamine	■
Eletriptan	◆
Eptinezumab	◆
Erenumab	◆
Ergotamine	■
Fremanezumab	◆
Frovatriptan	◆
Galcanezumab	◆
Methylergonovine	■
Naratriptan	◆
Pizotifen	◆
Rizatriptan	◆
Sumatriptan	◆
Zolmitriptan	◆

For personal use only. Not for distribution.

	Bulevirtide
Antiprotozoals	
Amodiaquine	◆
Artemether	◆
Artemisinin	◆
Artesunate	◆
Atovaquone	◆
Chloroquine	◆
Dihydroartemisinin	◆
Doxycycline	◆
Halofantrine	◆
Hydroxychloroquine	◆
Lumefantrine	◆
Mefloquine	◆
Nitazoxanide	◆
Pentamidine	◆
Primaquine	◆
Proguanil	◆
Pyrimethamine	◆
Quinine	■
Sodium stibogluconate	◆
Sulfadoxine	◆
Antipsychotic/Neuroleptics	
Amisulpride	◆
Aripiprazole	■
Asenapine	◆
Cariprazine	▲
Chlorpromazine	◆
Chlorprothixene	◆
Clozapine	◆
Flupentixol	◆
Fluphenazine	◆
Haloperidol	◆
Iloperidone	◆
Levomopromazine	◆
Lurasidone	◆
Olanzapine	◆
Paliperidone	◆
Perazine	◆
Periciazine	◆
Perphenazine	◆
Pimozide	■
Pipotiazine	◆
Prochlorperazine	◆
Promazine	◆
Quetiapine	■
Risperidone	◆
Sulpiride	◆
Tiapride	◆
Trifluoperazine	◆
Ziprasidone	◆
Zuclopentixol	◆
Antivirals	
Aciclovir	◆
Amantadine	◆
Ansumivab	◆
Brincidofovir	■
Brivudine	◆
Cidofovir	◆
Favipiravir	◆
Foscarnet	◆
Molnupiravir	◆
Nirmatrelvir/ritonavir	●
Oseltamivir	◆
Palivizumab	◆
Remdesivir	◆
Rimantadine	◆
Sotrovimab	◆
Tecovirimat	◆
Tixagevimab/cilgavimab	◆
Valaciclovir	◆
Zanamivir	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HDV Treatment

Charts created July 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
Anxiolytics/hypnotics/sedatives	
Alprazolam	◆
Amobarbital	◆
Bromazepam	◆
Bromperidol	◆
Buspirone	◆
Clobazam	◆
Clorazepate	◆
Clotiapine	◆
Diazepam	◆
Estazolam	◆
Flurazepam	◆
Lorazepam	◆
Lormetazepam	◆
Midazolam (oral)	■
Midazolam (parenteral)	■
Oxazepam	◆
Quazepam	◆
Temazepam	◆
Triazolam	◆
Zaleplon	◆
Zolpidem	◆
Zopiclone	◆
Beta Blockers	
Atenolol	◆
Bisoprolol	◆
Carvedilol	◆
Celiprolol	◆
Labetalol	◆
Metoprolol	◆
Nebivolol	◆
Oxprenolol	◆
Pindolol	◆
Propranolol	◆
Sotalol	◆
Timolol	◆
Bisphosphonates	
Alendronic acid	◆
Clodronate	◆
Ibandronic acid	◆
Pamidronate	◆
Risedronate	◆
Zoledronic acid	◆
Bronchodilators	
Acclidinium bromide	◆
Formoterol	◆
Indacaterol	◆
Ipratropium bromide	◆
Montelukast	◆
Omalizumab	◆
Reslizumab	◆
Salbutamol	◆
Salmeterol	◆
Theophylline	◆
Tiotropium	◆
Umeclidinium bromide	◆
Vilanterol	◆
Calcium Channel Blockers	
Amlodipine	◆
Diltiazem	◆
Felodipine	◆
Nicardipine	◆
Nifedipine	◆
Nisoldipine	◆
Nitrendipine	◆
Verapamil	◆

For personal use only. Not for distribution.

	Bulevirtide
Cancer Therapies	
Abiraterone	◆
Acalabrutinib	◆
Afatinib	◆
Alectinib	◆
Alpelisib	◆
Amivantamab	◆
Anastrozole	◆
Apalutamide	◆
Asciminib	◆
Atezolizumab	◆
Avelumab	◆
Axitinib	◆
Belantamab mafodotin	◆
Bendamustine	◆
Bevacizumab	◆
Bicalutamide	◆
Blinatumomab	◆
Bortezomib	◆
Bosutinib	◆
Brentuximab vedotin	◆
Capecitabine	◆
Carboplatin	◆
Carfilzomib	◆
Cemiplimab	◆
Cetuximab	◆
Chlorambucil	◆
Cisplatin	◆
Cyclophosphamide	◆
Daratumumab	◆
Dasatinib	◆
Dinutuximab beta	◆
Doxorubicin	◆
Durvalumab	◆
Erlotinib	◆
Elotuzumab	◆
Elranatamab	◆
Enzalutamide	◆
Epcoritamab	◆
Epirubicin	◆
Estramustine	◆
Etoposide	◆
Everolimus	■
Exemestane	◆
Fludarabine	◆
Gefitinib	◆
Gemcitabine	◆
Gemtuzumab ozogamicin	◆
Glofitamab	◆
Hydroxyurea (Hydroxycarbamide)	◆
Idarubicin	◆
Idelalisib	◆
Imatinib	◆
Inotuzumab ozogamicin	◆
Ipilimumab	◆
Irinotecan	◆
Isatuximab	◆
Ixazomib	◆
Lapatinib	◆
Letrozole	◆
Loncastuximab tesirine	◆
Medroxyprogesterone (oncology)	◆
Mercaptopurine	◆
Mesna	◆
Methotrexate	◆
Mitoxantrone	◆
Mogamulizumab	◆
Nilotinib	◆
Niraparib	◆
Nivolumab	◆

For personal use only. Not for distribution.

	Bulevirtide
Cancer Therapies Continued	
Obinutuzumab	◆
Ofatumumab	◆
Olaparib	■
Olaratumab	◆
Oxaliplatin	◆
Paclitaxel	■
Panitumumab	◆
Panobinostat	■
Pembrolizumab	◆
Pertuzumab	◆
Pomalidomide	◆
Ponatinib	■
Ramucirumab	◆
Retifanlimab	◆
Rituximab	◆
Ruxolitinib	◆
Sacituzumab govitecan	◆
Sunitinib	■
Tamoxifen	◆
Temsirolumus	■
Trastuzumab	◆
Trastuzumab deruxtecan	◆
Trastuzumab emtansine	■
Vinblastine	◆
Vincristine	◆
Vinorelbine	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HDV Treatment

Charts created July 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
Contraceptives and hormone replacement	
Conjugated estrogens (HRT)	◆
Desogestrel (POP)	◆
Desogestrel/ethinylestradiol (COC) (>20 µg)	◆
Desogestrel/ethinylestradiol (COC) (≤20 µg)	◆
Dienogest	◆
Drospirenone (POP)	◆
Drospirenone/estradiol (HRT)	◆
Drospirenone/ethinylestradiol (COC) (>20 µg)	◆
Drospirenone/ethinylestradiol (COC) (≤20 µg)	◆
Dydrogesterone/estradiol (HRT)	◆
Estradiol	◆
Ethinylestradiol (>20 µg)	◆
Ethinylestradiol (≤20 µg)	◆
Etonogestrel (implant)	◆
Etonogestrel (vaginal ring)	◆
Gestodene/ethinylestradiol (COC) (>20 µg)	◆
Gestodene/ethinylestradiol (COC) (≤20 µg)	◆
Levonorgestrel (Emergency Contraception)	◆
Levonorgestrel (HRT)	◆
Levonorgestrel (implant)	◆
Levonorgestrel (IUD)	◆
Levonorgestrel (POP)	◆
Levonorgestrel/ethinylestradiol (COC) (>20 µg)	◆
Levonorgestrel/ethinylestradiol (COC) (≤20 µg)	◆
Medroxyprogesterone (depot)	◆
Medroxyprogesterone (oral)	◆
Medroxyprogesterone/conjugated estrogens (HRT)	◆
Medroxyprogesterone/estradiol (HRT)	◆
Micronized progesterone (HRT)	◆
Norelgestromin/ethinylestradiol (patch)	◆
Norethisterone (Norethindrone) (depot injection)	◆
Norethisterone (Norethindrone) (POP)	◆
Norethisterone (Norethindrone)/estradiol (HRT)	◆
Norethisterone (Norethindrone) ethinylestradiol (COC)	◆
Norethisterone (Norethindrone)/mestranol (COC)	◆
Norgestimate/ethinylestradiol (COC)	◆
Norgestrel/conjugated estrogens (HRT)	◆
Norgestrel/ethinylestradiol (COC)	◆
Testosterone	◆
Erectile Dysfunction Agents	
Sildenafil	◆
Tadalafil	◆
Vardenafil	◆

For personal use only. Not for distribution.

	Bulevirtide
Gastrointestinal Agents	
Aluminium hydroxide	◆
Alverine citrate	◆
Antacids	◆
Aprepitant	◆
Bisacodyl	◆
Bismuth subsalicylate	◆
Cimetidine	◆
Cisapride	■
Cyclizine	◆
Docusate sodium	◆
Dantron	◆
Domperidone	■
Droperidol	◆
Esomeprazole	◆
Famotidine	◆
Granisetron	◆
Hyoscine (Scopolamine)	◆
Hyoscine butylbromide	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆
Ispaghula husk	◆
Lactulose	◆
Lafutidine	◆
Lansoprazole	◆
Linacotide	◆
Loperamide	◆
Lubiprostone	◆
Macrogol	◆
Mebeverine	◆
Mesalazine	◆
Methylcellulose	◆
Metoclopramide	◆
Naloxegol	◆
Nizatidine	◆
Omeprazole	◆
Ondansetron	◆
Pantoprazole	◆
Prucalopride	◆
Rabeprazole	◆
Ranitidine	◆
Roxatidine	◆
Senna	◆
Simeticone	◆
Sulfasalazine	●
Trimebutine	◆
Vonoprazan	◆
HCC Therapies	
Atezolizumab + bevacizumab	◆
Lenvatinib	◆
Pembrolizumab	◆
Regorafenib	◆
Sorafenib	◆
Hepatitis B Drugs	
Adefovir	◆
Entecavir	◆
Lamivudine	◆
Peginterferon alfa-2a	◆
Peginterferon alfa-2b	◆
Ribavirin	◆
Telbivudine	◆
Tenofovir alafenamide	◆
Tenofovir-DP	◆
Hepatitis C Drugs	
Daclatasvir	◆
Elbasvir/Grazoprevir	■
Glecaprevir/Pibrentasvir	■
Ledipasvir/Sofosbuvir	◆
OBV/PTV/r	●
OBV/PTV/r + Dasabuvir	●
Ravidasvir	◆
Ribavirin	◆
Sofosbuvir (SOF)	◆
SOF/Velpatasvir	◆
SOF/Velpatasvir/Voxilaprevir	■

For personal use only. Not for distribution.

	Bulevirtide
Herbals/Supplements/Vitamins	
Aloe vera	◆
Ashwagandha (Withania somnifera)	◆
Ascorbic acid (Vitamin C)	◆
Black cohosh (<i>A. racemosa</i>)	◆
Cat's claw (<i>U. tomentosa</i>)	◆
Colecalciferol (Vitamin D3)	◆
Cyanocobalamin (B12)	◆
Diosmin	◆
Echinacea	◆
Enteral feeds	◆
Eucalyptus globulus	◆
Ferrous sulfate	◆
Folic acid	◆
Garlic	◆
Ginger (<i>Z. officinale</i>)	◆
Ginkgo biloba	◆
Ginseng	◆
Goldenseal (<i>H. canadensis</i>)	◆
Grape seed extract	◆
Grapefruit juice	◆
Green tea (<i>C. sinensis</i>)	◆
Homeopathic remedies	◆
Inula racemosa	◆
Iodine	◆
Kava kava (<i>P. methysticum</i>)	◆
L-lysine	◆
Milk thistle	◆
Menthol	◆
Mucuna pruriens	◆
Niacin (Vitamin B3)	◆
Oral nutritional supplements	◆
Oregano oil	◆
Pyridoxine (Vitamin B6)	◆
Retinol (Vitamin A)	◆
Riboflavin (Vitamin B2)	◆
Saw palmetto (<i>S. repens</i>)	◆
St John's wort	◆
Thiamine (Vitamin B1)	◆
Turmeric (curcumin)	◆
Valerian	◆
Vitamin E	◆
Zinc	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HDV Treatment

Charts created July 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
HIV Drugs	
Entry/Integrase Inhibitors	
Albuvirtide	◆
Bictegravir/FTC/TAF	◆
Cabotegravir (oral)	◆
Cabotegravir/rilpivirine (LA)	▲
Dolutegravir	◆
Dolutegravir/rilpivirine	▲
Elvitegravir/cobi /FTC/TAF	●
Elvitegravir/cobi/FTC/TDF	●
Enfuvirtide	◆
Fostemsavir	◆
Ibalizumab-uiyk	◆
Lenacapavir	◆
Maraviroc	▲
Raltegravir	◆
NNRTIs	
Dapivirine	◆
Doravirine	▲
Doravirine/3TC/TDF	▲
Efavirenz	●
Etravirine	●
Nevirapine	◆
Rilpivirine	▲
Rilpivirine/dolutegravir	▲
Rilpivirine/FTC/TAF	▲
NRTIs	
Abacavir	◆
Didanosine	◆
Emtricitabine (FTC)	◆
Emtricitabine + TAF	◆
Emtricitabine + TDF	◆
Lamivudine	◆
Stavudine	◆
Tenofovir-DF	◆
Zidovudine	◆
Protease Inhibitors	
Atazanavir alone	●
Atazanavir/cobicistat	●
Atazanavir + ritonavir	●
Darunavir/cobicistat	●
Darunavir/cobi/FTC/TAF	●
Darunavir + ritonavir	●
Fosamprenavir	●
Indinavir	●
Lopinavir	●
Ritonavir	●
Tipranavir	●

For personal use only. Not for distribution.

	Bulevirtide
Hypertension/Heart Failure Agents	
Acebutolol	◆
Aliskiren	◆
Ambrisentan	■
Amiloride	◆
Azilsartan	◆
Benazepril	◆
Bendroflumethiazide	◆
Bosentan	■
Bumetanide	◆
Candesartan	◆
Captopril	◆
Chlorthalazide	◆
Chlortalidone	◆
Cilazapril	◆
Clevidipine	◆
Clonidine	◆
Doxazosin	◆
Enalapril	◆
Eplerenone	◆
Epoprostenol	◆
Eprosartan	◆
Fosinopril	◆
Furosemide	◆
Hydralazine	◆
Hydrochlorothiazide	◆
Iloprost	◆
Indapamide	◆
Irbesartan	●
Isradipine	◆
Ivabradine	◆
Lacidipine	◆
Lercanidipine	◆
Lisinopril	◆
Losartan	◆
Macitentan	◆
Methyldopa	◆
Metolazone	◆
Moxonidine	◆
Olmesartan	■
Perindopril	◆
Prazosin	◆
Quinapril	◆
Ramipril	◆
Ranolazine	◆
Rilmendidine	◆
Riociguat	◆
Sacubitril/valsartan	■
Selexipag	◆
Sildenafil	◆
Sodium nitroprusside	◆
Spirolactone	◆
Tadalafil	◆
Telmisartan	■
Torasemide	◆
Trandolapril	◆
Treprostinil	◆
Valsartan	■
Xipamide	◆
Zofenopril	◆
Illicit/Recreational	
Alcohol	◆
Amphetamine	◆
Cannabis	◆
Carfentanil	■
Cocaine	◆
Ecstasy (MDMA)	◆
Etizolam	◆
Fentanyl (Recreational)	■
GHB (Gamma-hydroxybutyrate)	■
Heroin	◆
LSD (Lysergic acid diethylamide)	◆
Mephedrone	◆
Methamphetamine	◆
Nicotine	◆
Nitazenes	▲
Phencyclidine (PCP)	■

For personal use only. Not for distribution.

	Bulevirtide
Immunosuppressants	
Abatacept	◆
Adalimumab	◆
Alemtuzumab	◆
Anakinra	◆
Azathioprine	◆
Baricitinib	◆
Basiliximab	◆
Belimumab	◆
Brodalumab	◆
Canakinumab	◆
Ciclosporin	●
Eculizumab	◆
Etanercept	◆
Fingolimod	◆
Golimumab	◆
Guselkumab	◆
Infliximab	◆
Ixekizumab	◆
Lenalidomide	◆
Mirikizumab	◆
Mycophenolate	◆
Pirfenidone	◆
Ravulizumab	◆
Risankizumab	◆
Sarilumab	◆
Secukinumab	◆
Sirolimus	■
Siltuximab	◆
Tildrakizumab	◆
Tocilizumab	◆
Tralokinumab	◆
Tacrolimus	■
Ublituximab	◆
Upadacitinib	◆
Ustekinumab	◆
Vedolizumab	◆
Lipid Lowering Agents	
Alirocumab	◆
Atorvastatin	■
Bempedoic acid	◆
Bezafibrate	◆
Evolocumab	◆
Ezetimibe	●
Fenofibrate	◆
Fish oils	◆
Fluvastatin	■
Gemfibrozil	◆
Icosapent ethyl	◆
Lovastatin	◆
Pitavastatin	■
Pravastatin	■
Omega-3-6-9 fatty acids	◆
Rosuvastatin	■
Simvastatin	■
Symptomatic	
Ergometrine (ergonovine)	■
Mifepristone	◆
Misoprostol	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with HDV Treatment

Charts created July 2024. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

	Bulevirtide
Parkinsonism Agents	
Benztpopine	◆
Carbidopa	◆
Orphenadrine	◆
Pramipexole	◆
Procyclidine	◆
Rasagiline	◆
Ropinirole	◆
PBC Agents	
Obeticholic acid	◆
Ursodeoxycholic acid	◆
Steroids	
Beclomethasone	◆
Betamethasone	◆
Budesonide	◆
Ciclesonide	◆
Clobetasol (topical)	◆
Clobetasone (topical)	◆
Dexamethasone ≤16 mg	◆
Dexamethasone >16 mg	◆
Fludrocortisone	◆
Flunisolide	◆
Fluticasone	◆
Hydrocortisone (topical)	◆
Methylprednisolone	◆
Mometasone	◆
Prednicarbate	◆
Prednisone	◆
Triamcinolone	◆
Urological Agents	
Alfuzosin	◆
Desmopressin	◆
Dutasteride	◆
Finasteride	◆
Mirabegron	◆
Silodosin	◆
Solifenacin	◆
Tamsulosin	◆
Tolterodine	◆
Trospium	◆

For personal use only. Not for distribution.

	Bulevirtide
Other Drugs	
Acamprosate	◆
Acetazolamide	◆
Acitretin	◆
Activated charcoal	◆
Allopurinol	◆
Atomoxetine	◆
Atropine	◆
Baclofen	◆
Bamlanivimab/Etesevimab	◆
Benralizumab	◆
Betahistine	◆
Bimatoprost	◆
Biperiden	◆
Brimonidine	◆
Brinzolamide	◆
Brolucizumab	◆
Bromocriptine	◆
Burosumab	◆
Calcitonin	◆
Calcium carbimide	◆
Calcium resonium	◆
Cannabidiol (CBD)	◆
Carbamazole	◆
Carisoprodol	◆
Casirivimab/imdevimab	◆
Cilostazol	◆
Clomifene	◆
Colchicine	■
Colestyramine	◆
Conivaptan	◆
Convalescent plasma (COVID-19)	◆
COVID-19 vaccines	◆
Crizanlizumab	◆
Cyclobenzaprine	◆
Cyproterone acetate	▲
Cytisine	◆
Darbepoetin	◆
Deferiprone	◆
Denosumab	◆
Dexamfetamine	◆
Dextromethorphan	◆
Disulfiram	◆
Donepezil	◆
Dorzolamide	◆
Dupilumab	◆
Eliglustat	◆
Emicizumab	◆
Epoetin alfa	◆
Etelcalcetide	◆
Faricimab	◆
Febuxostat	◆
Filgrastim	◆
Flibanserin	◆
Gadopentetate (gadolinium)	◆
Glucose monohydrate (IV)	◆
Glycerol phenylbutyrate	◆
Goserelin acetate	◆
Guanfacine	▲
Idarucizumab	◆
Influenza vaccine	◆
Interferon beta	◆
Isosorbide mononitrate	◆
Isotretinoin	◆
Lanadelumab	◆
Lanreotide	◆
Lebrikizumab	◆
Leuprorelin acetate	◆
Levothyroxine	■
Lisdexamfetamine	◆
Lofexidine	◆
Lumacaftor/vacaftor	◆
Magnesium	◆
Melatonin	◆
Memantine	◆
Mepolizumab	◆
Methimazole (Thiamazole)	◆
Methylphenidate	◆
Minoxidil	◆
Modafinil	◆

For personal use only. Not for distribution.

	Bulevirtide
Other Drugs Continued	
Naftidrofuryl	◆
Nalmefene	◆
Naloxone	◆
Naltrexone	◆
Neostigmine	◆
Nicorandil	◆
Nusinersen	◆
Ocrelizumab	◆
Orlistat	◆
Penicillamine	◆
Pentoxifylline	◆
Phenylephrine	◆
Pilocarpine	◆
Piracetam	◆
Potassium	◆
Propylthiouracil	◆
Protamine sulphate	◆
Pseudoephedrine	◆
Pyridostigmine	◆
Raloxifene	◆
Romosozumab	◆
Rozanolixizumab	◆
Sevelamer	◆
Strontium ranelate	◆
Thalidomide	◆
Triptorelin	◆
Varenicline	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.